ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Metacrine Inc

Metacrine Inc (MTCR)

0.4949
0.00
( 0.00% )
Updated: 20:00:00

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
0.4949
Bid
0.4601
Ask
0.475
Volume
-
0.00 Day's Range 0.00
0.00 52 Week Range 0.00
Previous Close
0.4949
Open
-
Last Trade
Last Trade Time
-
Average Volume (3m)
-
Financial Volume
-
VWAP
-

MTCR Latest News

Metacrine and Equillium Mutually Agree to Terminate Definitive Merger Agreement

LA JOLLA, Calif., Dec. 23, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR) and Equillium, Inc. today announced the mutual termination of their previously announced definitive merger...

Metacrine Reports Third-Quarter 2022 Results

SAN DIEGO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company developing differentiated therapies for patients with gastrointestinal...

Equillium to Acquire Metacrine in All-Stock Transaction

Expected to add $33 million in cash at closing to Equilliumโ€™s balance sheet and extend operating runway into 2024 Acquisition includes novel drug candidate MET642, an orally delivered Phase 2...

Metacrine Reports Second-Quarter 2022 Results

SAN DIEGO, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal...

Metacrine Reports First-Quarter 2022 Results

SAN DIEGO, May 12, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal...

Metacrine Reports Fourth-Quarter 2021 Results

SAN DIEGO, March 30, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal...

Metacrine Announces Executive Leadership Changes

SAN DIEGO, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal...

Metacrine Updates IBD Clinical Development Strategy and Implements Restructuring Plan

U.S. FDA clears IND to evaluate MET642 for the treatment of ulcerative colitisSufficient capital to complete Phase 2 IBD trial SAN DIEGO, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc...

Metacrine Announces Resignation of Chief Medical Officer

SAN DIEGO, Dec. 27, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal and...

Metacrine Reports Third-Quarter 2021 Results

SAN DIEGO, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal and...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
DRUGBright Minds Biosciences Inc
$ 24.6227
(888.86%)
89.51M
NIVFNewGenIvf Group Ltd
$ 2.02
(167.73%)
119.55M
ZPTAZapata Computing Holdings Inc
$ 0.1303
(69.22%)
541.96M
GRTSGritstone bio Inc
$ 0.0732
(35.56%)
334.46M
WLGSWang and Lee Group Inc
$ 2.96
(34.55%)
2.62M
SEELSeelos Therapeutics Inc
$ 1.36
(-44.49%)
1.51M
PIXYShiftPixy Inc
$ 6.3161
(-34.62%)
930.73k
YYAIConnexa Sports Technologies Inc
$ 3.95
(-34.06%)
331.36k
NTBLNotable Labs Ltd
$ 0.2729
(-31.78%)
1.83M
AMLIAmerican Lithium Corporation
$ 0.83245
(-25.00%)
3.2M
ZPTAZapata Computing Holdings Inc
$ 0.1303
(69.22%)
541.96M
GRTSGritstone bio Inc
$ 0.0732
(35.56%)
334.46M
NVDANVIDIA Corporation
$ 132.095
(-4.33%)
298.34M
SQQQProShares UltraPro Short QQQ
$ 7.2599
(3.86%)
145.87M
NIVFNewGenIvf Group Ltd
$ 2.02
(167.73%)
119.55M

MTCR Discussion

View Posts
Renee Renee 1 year ago
MTCR: Liquidation/Final Distribution (no distribution notes by FINRA)

FINRA deleted symbol:

https://otce.finra.org/otce/dailyList?viewType=Deletions
๐Ÿ‘๏ธ0
Renee Renee 2 years ago
MTCR delisted from the Nasdaq to the OTC:

https://otce.finra.org/otce/dailyList?viewType=Additions
๐Ÿ‘๏ธ0
HoldEm777 HoldEm777 2 years ago
Insider buying and a buyoutโ€ฆ may be already baked in but probably not.
๐Ÿ‘๏ธ0
CrispCris CrispCris 2 years ago
Double down
๐Ÿ‘๏ธ0
DewDiligence DewDiligence 3 years ago
50% workforce reduction in R&D:

https://www.globenewswire.com/news-release/2022/02/11/2383703/0/en/Metacrine-Updates-IBD-Clinical-Development-Strategy-and-Implements-Restructuring-Plan.html

What took so long?
๐Ÿ‘๏ธ0
pitacorp pitacorp 3 years ago
you sure hit the nail on the head with that brilliant conclusion... 4 month old news is going to make this dive now???
๐Ÿ‘๏ธ0
KeepOn KeepOn 3 years ago
Something happening here?
๐Ÿ‘๏ธ0
mining101 mining101 3 years ago
Who is following that move??
๐Ÿ‘๏ธ0
mining101 mining101 3 years ago
Super bullish close
๐Ÿ‘๏ธ0
JMoneyHoops JMoneyHoops 3 years ago
Yes lost big unfortunately hopefully a bounce PM the love/hate of biotech plays
๐Ÿ‘๏ธ0
DewDiligence DewDiligence 3 years ago
MTCR addendum: #msg-166460862.
๐Ÿ‘๏ธ0
DewDiligence DewDiligence 3 years ago
MTCR -50%/AH on discontinuation of FXR/NASH program:

https://www.globenewswire.com/news-release/2021/10/21/2318743/0/en/Metacrine-Reports-Interim-Results-for-MET642-Phase-2a-Trial-in-Patients-with-NASH-and-Announces-a-Strategic-Re-Prioritization-of-Its-Clinical-Development-Programs.html โ€œAfter a rigorous assessment of our NASH and IBD programs, including the significant capital and resources required to progress these large clinical development programs, we have made the decision to focus Metacrineโ€™s clinical development effort and financial resources on moving MET642 into a Phase 2 trial in IBD in the first half of 2022 and to halt future development of the FXR program in NASH. This decision was influenced in part by a potential delay in confirming appropriate safety margins in our long-term toxicology work that would impact the timing of future NASH studies, but is unlikely to impact timelines for the IBD clinical program.โ€ That was in the seventh paragraph of the PR, LOL.
๐Ÿ‘๏ธ0
JMoneyHoops JMoneyHoops 3 years ago
Data soon
๐Ÿ‘๏ธ0
DewDiligence DewDiligence 3 years ago
MTCR 1Q21 resultsโ€”3/31/21_cash=$84.5M:

https://finance.yahoo.com/news/metacrine-accelerates-met409-clinical-development-200500397.html
๐Ÿ‘๏ธ0
DewDiligence DewDiligence 4 years ago
MTCR 4Q20 resultsโ€”12/31/20 cash=$96.2M:

https://www.globenewswire.com/news-release/2021/03/18/2195229/0/en/Metacrine-Provides-Business-Update-and-Reports-Fourth-Quarter-and-Full-Year-2020-Financial-Results.html
๐Ÿ‘๏ธ0
DewDiligence DewDiligence 4 years ago
MTCR starts phase-2a for MET642โ€”the follow-on FXR agonist to MET409:

https://finance.yahoo.com/news/metacrine-initiates-phase-2a-trial-113000073.html The Phase 2a clinical trial is a 16-week, randomized, placebo-controlled, multi-center trial evaluating the safety, tolerability and pharmacological activity (as measured by liver fat reduction) of MET642 (3 mg and 6 mg) vs placebo. An interim analysis is planned in the fourth quarter of 2021, after approximately 60 patients have completed 16 weeks of treatment. Topline trial results of up to 180 patients are expected to be reported in the first half of 2022. See #msg-162210410 for related info.
๐Ÿ‘๏ธ0
DewDiligence DewDiligence 4 years ago
MET-409 phase-1b data in NASH donโ€™t look so good:

#msg-162210410
๐Ÿ‘๏ธ0
doogdilinger doogdilinger 4 years ago
Up +7% pm
๐Ÿ‘๏ธ0
doogdilinger doogdilinger 4 years ago
Awesome sauce crude buddy, catchin' up on the DD with ya ty
๐Ÿ‘๏ธ0
doogdilinger doogdilinger 4 years ago
Perfect! I'm playing way more big board this month than pennies! The money flow on big board runners has been utter insanity so far this month!
๐Ÿ‘๏ธ0
doogdilinger doogdilinger 4 years ago
Nice crude buddy;)
๐Ÿ‘๏ธ0
crudeoil24 crudeoil24 4 years ago
IPO was last month > 9/16/2020.
๐Ÿ‘๏ธ0
crudeoil24 crudeoil24 4 years ago
Metacrine shares are trading higher after the company announced it is presenting new data from its MET409 program in NASH at AASLD's The Liver Meeting Digital Experience.
๐Ÿ‘๏ธ0
crudeoil24 crudeoil24 4 years ago
Metacrine, Inc. is a United States-based biotechnology company. The Company is engaged in developing therapeutics for metabolic diseases. The Company leverages approximately two mechanistically distinct programs to target type 2 diabetes, NASH and other metabolic diseases and liver disorders. The Company focuses on advancing research in nuclear hormone receptors for treatment of metabolic diseases.
๐Ÿ‘๏ธ0

Your Recent History

Delayed Upgrade Clock